Ion Beam Applications (IBAB) Q1 2026 TU earnings summary

Executive summary

• Solid commercial momentum in Q1 2026, led by RadioPharma Solutions and an active Proton Therapy pipeline.

• Backlog stable at €1.6 billion, with €0.73 billion in equipment and €0.83 billion in services.

• Product innovation milestones achieved, including regulatory progress for actinium-225 supply and new launches in dosimetry and imaging.

• Cost-reduction measures initiated to realign the cost base and improve profitability from H2 2026.

Financial highlights

• FY2026 adjusted EBIT guidance reaffirmed at a minimum of €32 million.

• Net debt stable at €57 million as of March 31, 2026, with €15 million of revolving credit facilities used.

• Share buyback program ongoing, with 279,188 shares purchased out of a 400,000 target.

Outlook and guidance

• FY2026 performance on track with guidance; adjusted EBIT of at least €32 million expected.

• Mid-term outlook (2024-2028): revenue growth at 5-7% CAGR, OPEX up to 30% of sales, adjusted EBIT around 10% of revenue by 2028.

• Net financial position expected to remain stable in H1 2026, improving in H2 2026 and accelerating in 2027.